This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
hibobi: Unlocking Global Success with Localization Strategy in Diverse Markets
The market in the Middle East has recently gained considerable attention from entrepreneurs worldwide. The hibobi Group, a pioneer in this emerging market, has unique insights in branding and supply chain construction.
Updated 2 hours ago
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Defining key tasks and accelerating the construction of new urbanization
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
WaveFront Ventures: How Can Chinese Companies Win the Global Robotic Race
Mar 24, 2023 02:02 PM
CIRCUE: AI Drives the Revolution of Energy, Leading a Sustainable Future
Mar 23, 2023 12:26 PM